News | Radiation Therapy | January 03, 2017

NCCN Guidelines Recommend Y-90 Microspheres for Metastatic Colorectal Cancer Treatment

Expert panel reaches uniform consensus that yttrium-90 microspheres is an appropriate option for patients with colorectal liver metastases

metastatic colorectal cancer, mCRC, Sirtex, NCCN guidelines, Y-90 microspheres

January 3, 2017 — Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. This designation denotes there is uniform consensus among the NCCN panel that selective internal radiation therapy (SIRT) with yttrium-90 microspheres is an appropriate option in patients with liver dominant, chemotherapy resistant colorectal disease (mCRC). This recommendation places SIR-Spheres Y-90 resin microspheres at the same designation as the recommended mCRC systemic chemotherapeutic regimens.

The new NCCN Guidelines are available online at https://www.nccn.org/professionals/physician_gls/f_guidelines.asp

According to Sirtex Americas CEO Kevin Richardson, the company has positive signals in the first-line setting from the results to-date of the SIRFLOX study1 and expects results from the SIRFLOX, FOXFIRE and FOXFIRE Global studies in the first half of 2017.

These findings are also supported by the landmark MORE study2, a large retrospective analysis conducted in the United States with SIR-Spheres Y-90 resin microspheres in more than 600 mCRC patients. The MORE study helped to increase the understanding of SIRT as a treatment option for patients who have failed multiple lines of chemotherapy, while highlighting the positive aspects of the safety and efficacy of the protocol for patients of all ages.

“Clinical research has shown that SIRT brings patients with colorectal liver metastases improved and prolonged quality of life,” said lead investigator of the MORE study, Andrew S. Kennedy, M.D., FACRO, director, radiation oncology research at Sarah Cannon Research Institute, Nashville, Tenn. “We look forward to expanding access to this outpatient procedure, which has demonstrated minimal side effects, to improve outcomes for this population of patients and advance the standard of care.”

SIR-Spheres Y-90 resin microspheres are the first and only microspheres with U.S. Food and Drug Administration (FDA) premarket approval (PMA) for colorectal cancer that has metastasized to the liver.3

For more information, visit www.sirtex.com.

References

1. van Hazel GA, Heinemann V, Sharma NK et al. SIRFLOX: Randomized Phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2016; 34: 1723–1731.

2. Kennedy AS, Ball D, Cohen SJ et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for 90Y resin microspheres. Journal of Gastrointestinal Oncology. 2015; 6: 134–142

3. SIR-Spheres microspheres (Yttrium-90 Microspheres) Product Information. Available at: www.sirtex.com/us/clinicians/package-insert/. Assessed on December 8, 2016.

 

Related Content

IBA Installs Three Proteus One Systems in One Week
News | Proton Therapy | April 28, 2017
April 28, 2017 — IBA announced the delivery and rigging of three Proteus One treatment rooms in less than a week at c
Nottingham City Hospital Selects RayStation for Radiotherapy Treatment Planning
News | Treatment Planning | April 28, 2017
Nottingham City Hospital in the United Kingdom has chosen RayStation as the new treatment planning system for its...
IBA Dosimetry Americas Announces New Exclusive Canadian Distributor for Radiotherapy Products
News | Radiation Therapy | April 28, 2017
April 28, 2017 — IBA (Ion Beam Applications S.A.) announced the Dosimetry Americas division has recently partnered wi
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the devel
Early Stereotactic Radiosurgery Improves Outcomes for Nonfunctioning Pituitary Macroadenoma Patients
News | Radiation Therapy | April 27, 2017
Jason P. Sheehan, M.D., Ph.D., FAANS, winner of the Leksell Radiosurgery Award, presented his research on stereotactic...
Nine New Disease Sites Added to the NCCN Radiation Therapy Compendium
News | Radiation Therapy | April 26, 2017
April 26, 2017 — The National Comprehensive Cancer Network (NCCN) continues to build its NCCN Radiation Therapy Compe
Precision Medicine Poised to Change Brain Tumor Diagnostics and Treatment
News | Radiation Therapy | April 26, 2017
April 26, 2017 — A new report on the brain cancer diagnostics market projects that up to 78,000 new cases of primary
Elekta Highlights Leksell Vantage System for Stereotactic Neurosurgery at AANS 2017
News | Radiation Therapy | April 24, 2017
Elekta announced that its Leksell Vantage Stereotactic System, will be highlighted at the American Association of...
News | Prostate Cancer | April 24, 2017
April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal
New Clinical Data on Xoft System Presented at American Brachytherapy Society Annual Meeting
News | Brachytherapy Systems, Women's Healthcare | April 20, 2017
iCAD Inc. announced that updated clinical data on the use of intraoperative radiation therapy (IORT) using the Xoft...
Overlay Init